|Advaxis Receives Patent in Japan for ADXS-HPV; Bayer Healthcare Receives CEO Cancer Gold Standard Accreditation|
|By Staff and Wire Reports|
|Tuesday, 18 March 2014 18:54|
Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.
"Receiving this patent in Japan for our proprietary immunotherapy product candidate, ADXS-HPV, to be used in treating patients with late-stage cervical cancer is an important milestone," commented Daniel J. O'Connor, Chief Executive Officer of Advaxis. "This expands our patent portfolio which already has over 40 patents issued and over 40 patents pending worldwide. With licensing agreements established in Asia, with Global BioPharma, and India, with Biocon Ltd., Advaxis is positioned for global development and commercialization of our immunotherapies to treat cervical cancer. Expanding the protection of our intellectual property is a major component of this strategy."
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that, following the recent FDA acceptance of the Company's IND for MDX, the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD.
athenahealth, Inc.(Nasdaq:ATHN), a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, and Saint Peter's Healthcare System today announced that Saint Peter's has selected athenahealth's athenaOne® suite of cloud-based EHR, practice management, and patient communication services across its multi-specialty physician practices, comprised of 176 hospital- and clinic-based physicians in New Brunswick, New Jersey, and New York City.
BioCorRx, Inc. (OTCQB: BICX), a leader in addiction treatment and rehabilitation programs, announced it has entered into a letter of intent to sell the exclusive license and distribution rights of its Start Fresh Program to Fresh Start Private Midwest, LLC.
Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, March 24, 2014 at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014, after the U.S. financial markets close.
FutureWorld (OTCQB: FWDG), a U.S. Diversified Holding Company formed to capitalize on the burgeoning technology markets globally, announces today that it has created an advisory board for a new planned division called HempTechRX.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock.
Lipocine Inc. (OTCQB:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group.
Mascota Resources Corp (OTCBB: MACR) announced today that it has signed a letter of intent to acquire Canada Cannabis Corp, a privately owned Canadian company.
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC, whereby Nanosphere has the right to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time. Aspire Capital is an existing Nanosphere shareholder, having invested in the Company's most recent underwritten public offering in September 2013.
Nature's Sunshine Products, Inc. (Nasdaq:NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, today announced that the Company's regular quarterly cash dividend of $0.10 per share will be payable on April 7, 2014, to shareholders of record as of the close of business on March 28, 2014.
NeuroBioPharm Inc., a Neptune Technologies & Bioressources Inc. subsidiary (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013.
Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the full year ending December 31, 2013, and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD).
Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana.
SANUWAVE Health, Inc. (OTCBB:SNWV) today announced it has closed a private placement with institutional and select accredited investors raising total gross proceeds of $10.1 million.
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has completed its previously announced underwritten public offering of 2,125,000 shares of its common stock at a price of US$28.50 per share for aggregate gross proceeds of US$60,562,500, before deducting underwriting discounts and commissions and other estimated offering expenses.